Skinvisible

Skinvisible Equity

The The Equity of Skinvisible (SKVI) as of Oct 20, 2026 is -10.26 M USD. In the previous year, The Equity was -9.22 M USD — a change of 11.27% (lower).

Equity

-10.26 MUSD

YoY

11.27%

Last updated:

In 2025, Skinvisible's equity was -10.26 M USD, a 11.27% increase from the -9.22 M USD equity in the previous year.

The Skinvisible Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
-4.72 M USD
Jan 1, 2019
-3.01 M USD
Jan 1, 2020
-4.45 M USD
Jan 1, 2021
-5.42 M USD
Jan 1, 2022
-6.64 M USD
Jan 1, 2023
-9.02 M USD
Jan 1, 2024
-9.22 M USD
Jan 1, 2025
-10.26 M USD
The Skinvisible Equity history
YEAREquityYoY
-10.26 MUSD+11.27%
-9.22 MUSD+2.22%
-9.02 MUSD+35.88%
-6.64 MUSD+22.62%
-5.42 MUSD+21.57%
-4.45 MUSD+48.14%
-3.01 MUSD-36.28%
-4.72 MUSD-30.18%
-6.76 MUSD+10.66%
-6.11 MUSD+7.88%
-5.66 MUSD+30.14%
-4.35 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Skinvisible Stock analysis

What does Skinvisible do? Skinvisible Inc develops and patents the Invisicare polymer delivery system, which enhances the delivery of active ingredients in topical skin care products. The company has formulated over forty topical skin products using Invisicare, with Pivotal being the patented technology that enables extended duration of active ingredients on the skin. Invisicare specifically carries water-insoluble and certain cationic active ingredients in water-based products without alcohol, silicones, waxes, or organic solvents. The firm's revenue comes from licensing the Invisicare technology to partners who develop and sell skin care products incorporating this delivery system. Skinvisible Inc's primary customers are pharmaceutical and cosmetic companies seeking to improve the efficacy of their topical skin care formulations. These companies purchase the Invisicare technology to integrate into their own product lines, leveraging the extended delivery duration and compatibility with water-based formulations. The company does not sell end-user products but focuses on technology licensing for partners who manufacture and market the final skin care products. The business model relies on the patent protection of Invisicare, which allows Skinvisible to generate revenue through licensing agreements. Partners pay for the right to use the technology in their products, with the company's focus on developing and protecting the polymer delivery system as its core asset. The firm's product portfolio includes over forty topical skin products developed using Invisicare, but these are not sold directly by Skinvisible Inc. Skinvisible is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Skinvisible's Equity

Skinvisible's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Skinvisible's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Skinvisible's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Skinvisible's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Skinvisible’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Skinvisible stock

The Equity of Skinvisible is -10.26 M USD in 2025.

The Equity of Skinvisible changed from -9.22 M USD to -10.26 M USD, representing a 11.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Skinvisible since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Skinvisible historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Skinvisible

All Key Metrics — Skinvisible